2 Magnificent Quantum Computing Stocks to Buy and Hold for 10 Years

IonQ launched its Superion 256 trapped-ion quantum platform in September and demonstrated photonic interconnects linking two independent quantum systems, supporting its strategy to become a scalable quantum hardware and services supplier. IBM committed more than $10 billion to quantum computing over the next five years and targets delivery of its fault-tolerant Quantum Starling system in 2029, designed to execute roughly 20,000 times more operations than current machines. The article presents both companies as long-term quantum-computing investments, with IonQ offering direct exposure and IBM providing a more diversified infrastructure-led route.

Analysis

IONQ is the higher-beta expression of quantum capex, but the equity’s near-term value is governed less by technical milestones than by conversion of bookings into revenue, cash burn, and credible commercial utilization. Its trapped-ion and networking approach could create a differentiated architecture if modular systems prove scalable; that outcome would also benefit SKYT through advanced-manufacturing validation. The key risk is that hardware road maps remain technically impressive but economically premature, leaving IONQ vulnerable to multiple compression whenever quarterly bookings, backlog conversion, or gross-margin progression disappoints.

IBM’s quantum program is strategically more valuable as a customer-retention and hybrid-cloud attach product than as a stand-alone earnings driver. Quantum capability can reinforce IBM Consulting, Red Hat, and large regulated-enterprise relationships, but it is unlikely to move consolidated EPS materially over the next 12-24 months; the market should not capitalize a distant quantum revenue stream at IONQ-like growth multiples. IBM’s larger balance sheet also gives it the option to absorb prolonged R&D cycles, creating a competitive funding disadvantage for pure plays including IONQ, RGTI and QBTS.

The consensus error is treating qubit counts and laboratory demonstrations as equivalent to commercial scaling. The investable inflection is repeatable error-corrected performance tied to paid workloads, not system announcements. Over 1-3 months, conference demonstrations, government awards, and hyperscaler distribution announcements can sustain retail-led momentum; over 6-18 months, revenue quality and cash consumption should separate platform vendors from capital-market-dependent developers. Falsify the cautious pure-play view if IONQ demonstrates sustained backlog conversion, rising recurring cloud/service mix, and a materially extended cash runway without dilutive financing.

Key Decisions for Investors

• Maintain IBM as the preferred low-volatility quantum exposure over a 6-18 month horizon; treat quantum as upside optionality while underwriting the position on software, consulting, and free-cash-flow execution. Reassess if core software growth weakens or management raises quantum investment without a clear return framework.
• Do not initiate a directional IONQ long solely on technology announcements. Create an alert for post-earnings evidence of bookings converting to recognized revenue and a stable-to-improving cash-burn trajectory; those data would justify a tactical 3-6 month long, while a guidance cut or dilutive capital raise is a short/avoid trigger.
• For a relative-value expression, consider long IBM / short a basket of pre-profit quantum pure plays (IONQ, RGTI, QBTS) after sharp sector rallies rather than at current momentum lows. The thesis is funding durability and enterprise distribution versus valuation sensitivity to distant commercialization; target a 10-15% relative move over 6-12 months, with risk limits if a major government procurement or independently verified fault-tolerance milestone changes the commercialization timetable.
• Monitor SKYT only as a second-order supply-chain watch item, not a quantum recommendation. A meaningful opportunity requires disclosed production volumes, wafer-content economics, and customer concentration data; absent those disclosures, quantum-related manufacturing claims are unlikely to be material to earnings.